Technology NetworksThe global cancer stem cells market size is expected to reach USD 1.6 billion by 2025PR Newswire (press release)LONDON, May 29, 2018 /PRNewswire/ — Cancer Stem Cells Market Share, Size & Trends Analysis Report By MoA (Stem Cell … Continue reading
Genetic Literacy ProjectThe real sustainability revolution in farming is New Breeding Techniques like CRISPR. Why are organic farmers …Genetic Literacy ProjectAn illustrative example is the new gene-edited mushroom––a common white mushroom (Agaricus … Continue reading
Expert ConsultingSecond OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy Held in Shanghai, Promoting …PR Newswire (press release)On May 26, 2018, the Second OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Ther… Continue reading
WeAreGreenBay.comHealthWatch: Stem Cell Treatments: Buyers Beware!WeAreGreenBay.comCHICAGO, Ill. (Ivanhoe Newswire) — You name the pain, and a stem cell clinic seems to be springing up to fix it, from knee pain to glaucoma. But some of these clinics m… Continue reading
Business Wire (press release)Allergy Therapeutics plc – Positive new data with house-dust mite immunotherapyNasdaqHouse-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement ~. ~ Allergy experts pres… Continue reading
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene …GlobeNewswire (press release)LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 29, 2018 (GLOBE NEWSWIRE) — uniQure N.V. (… Continue reading
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene …GlobeNewswire (press release)LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 29, 2018 (GLOBE NEWSWIRE) — uniQure N.V. (… Continue reading
European Biotechnology |
New way to safer CAR–T cell therapies
European Biotechnology These adverse effects (AEs), which could be life-threatening, are associated with administration of CAR–T cell therapies and have been managed so far by co-administration of IL6-receptor blockers such as Roche’s tocilizumab, which can prevent CRS but … |